Skip to main content

Anterior Resection Syndrome

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Dong-A ST
Dong-A STKorea - Seoul
1 program
1
RamosetronPhase 11 trial
Active Trials
NCT02869984Unknown100

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Dong-A STRamosetron

Clinical Trials (1)

Total enrollment: 100 patients across 1 trials

Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome

Start: Aug 2016100 patients
Phase 1Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.